Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? N. RamnathD. TanS. Ferrone Original Article 27 September 2005 Pages: 891 - 899
Photodynamic therapy-generated vaccine for cancer therapy Mladen KorbelikJinghai Sun Original Article 08 October 2005 Pages: 900 - 909
Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma F. L. ZhouW. G. ZhangS. H. Liu Original Article 29 September 2005 Pages: 910 - 917
Increased expression of TGF-β1 reduces tumor growth of human U-87 Glioblastoma Cells in vivo Jen-Jung PanWei-Jen ChangSteven J. Greenberg Original Article 27 September 2005 Pages: 918 - 927
Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: implications for diphtheria fusion protein therapy Philip D. HallDebajyoti SinhaArthur E. Frankel Original Article 28 January 2006 Pages: 928 - 932
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors Christine S. BundellConnie JackamanDelia J. Nelson Original Article 11 November 2005 Pages: 933 - 947
Cytomodulation of interleukin-2 effect by l-2-oxothiazolidine-4-carboxylate on human malignant melanoma Maite del OlmoAna Alonso-VaronaTeodoro Palomares Original Article 12 October 2005 Pages: 948 - 957
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients Lorenzo PillaRoberto PatuzzoGiorgio Parmiani Original Article 08 October 2005 Pages: 958 - 968
Conference report and introduction to the symposium papers L. G. Durrant Meeting Report 25 February 2006 Pages: 970 - 972
Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients Nicholas F. S. WatsonLindy G. DurrantIan Spendlove Symposium Paper 03 September 2005 Pages: 973 - 980
Immunosenescence, suppression and tumour progression G. PawelecS. KochC. Gouttefangeas Symposium Paper 06 December 2005 Pages: 981 - 986
Complement decay accelerating factor (DAF)/CD55 in cancer Ian SpendloveJudith M. RamageLindy G. Durrant Symposium Paper 17 February 2006 Pages: 987 - 995
The identification of human tumour antigens: current status and future developments Amanda K. MilesBalwir Matharoo-BallRobert C. Rees Symposium Paper 12 January 2006 Pages: 996 - 1003
The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2 Judith M. RamageIan SpendloveLindy G. Durrant Symposium Paper 12 January 2006 Pages: 1004 - 1010
Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy Luciene LopesKate FletcherMary Collins Symposium Paper 26 November 2005 Pages: 1011 - 1016
An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia Lucas ChanNicola R. HardwickFarzin Farzaneh Symposium Paper 01 February 2006 Pages: 1017 - 1024
Cancer vaccines as a therapeutic modality: the long trek A. G. DalgleishM. A. Whelan Symposium Paper 28 February 2006 Pages: 1025 - 1032